Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer

Shengxiu He, Liang Wang, Yan Sun, Huakun Du, Xiao-Min YuFrontiers in Immunology 2023 · DOI

Abstract

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but often cause immune-related adverse events (irAEs), frequently leading to permanent treatment discontinuation. This case report details a 34-year-old patient with advanced renal clear cell cancer (RCC) who experienced severe Grade III/IV irAEs during initial therapy. Following recovery and a multidisciplinary discussion, the patient was successfully rechallenged with a fully humanized PD-1 inhibitor, zimberelimab. The patient achieved a partial response and maintained remission for 14 months without recurrent toxicity, suggesting that switching to fully humanized antibodies may be a viable strategy for patients who previously exhausted options due to toxicity.

Introduction

The rise of immune checkpoint inhibitors (ICIs) has significantly improved outcomes for various malignancies. However, the "unbraking" of the immune system can lead to immune-related adverse events (irAEs), where the body attacks its own tissues. Clinical guidelines typically mandate the permanent cessation of ICI therapy following Grade 4 toxicities. Paradoxically, the occurrence of irAEs often correlates with a robust anti-tumor response. For patients with advanced renal clear cell cancer (RCC), there is limited data on the safety and efficacy of restarting immunotherapy after a severe reaction. This report explores the potential of "rechallenging" such patients using alternative ICI agents.

Case Presentation and Methods

A 34-year-old female with metastatic RCC was initially treated with sintilimab (a PD-1 inhibitor) and pazopanib (a VEGF inhibitor). Shortly after initiation, she developed Grade IV fever and Grade III hepatic, hematologic, and ocular toxicities. Treatment was halted, and high-dose intravenous methylprednisolone was administered to manage the systemic inflammation.

Following full recovery, a multidisciplinary team (MDT) evaluated the possibility of an immune restart. The strategy involved switching the PD-1 inhibitor to zimberelimab, a fully humanized monoclonal antibody. Zimberelimab's structure is designed to be less immunogenic than chimeric or partially humanized alternatives. This was paired with a modified dose of pazopanib to manage treatment-induced hypertension.

Results

The rechallenge proved highly effective. After two cycles of the new regimen, the patient demonstrated a partial response (PR). Most notably, the patient experienced no recurrent irAEs throughout the 14-month follow-up period.

Initial right lung lesion measuring 13mm prior to the successful rechallenge.

Imaging confirmed significant tumor reduction. The right lung lesion, which measured 13mm at one stage of the disease progression, eventually reached complete remission.

Follow-up CT scan demonstrating complete remission of the right lung lesion.

Additionally, a left lung lesion stabilized at a reduced size of 5mm. The patient remained in continuous remission at the last follow-up.

Discussion

This case highlights two critical concepts in modern oncology:

  1. The "Humanized" Advantage: The success of zimberelimab in this patient supports the hypothesis that the molecular structure of an ICI impacts its safety profile during rechallenge. Fully humanized antibodies may reduce the risk of triggering the same immune overreactions seen with older agents.
  2. Toxicity as a Proxy for Efficacy: The patient's rapid response during the initial toxic phase reinforces the link between immune activation and tumor destruction. Rather than abandoning immunotherapy entirely, a strategic "restart" can capture the clinical benefits while mitigating risks.

Conclusion

Rechallenging with immunotherapy after severe irAEs is an emerging strategy that offers hope for patients who show early signs of response but suffer from toxicity. While this single-case success is encouraging, it underscores the need for careful patient selection, multidisciplinary oversight, and further research into the comparative safety of fully humanized ICIs in the rechallenge setting.

Summary updated

Abstract

With the rapidly evolving of immune checkpoint inhibitors (ICIs), it has shown remarkable clinical benefits in treating various cancers. However, immune-related adverse events (irAEs) remain a significant challenge in the management of patients undergoing immunotherapy. There are limited data about immunotherapy re-challenge in patients with renal clear cell cancer who had irAE in the initial ICI therapy. In this study, we reported the case of a patient with advanced renal clear cell cancer who developed serious irAEs but also achieved a partial remission of tumor after ICI combined with pazopanib in the first-line treatment. After intravenous methylprednisolone therapy for two weeks, the patient fully recovered from treatment-related toxicities. After a multidisciplinary treatment (MDT) discussion and a communication with the patient, the decision was made to undergo a new fully humanized programmed death 1 (PD-1) agent, zimberelimab, combined with pazopanib for immune restart therapy. After two cycles of treatment, the patient demonstrated a partial response (PR), and the disease remained in continuous remission without any irAE at our last follow-up after 14 months' treatment. Re-challenging with immunotherapy after irAEs is an emerging strategy that offers the potential for additional clinical benefits to previously responding patients. However, careful patient selection and monitoring are essential to maximize the safety and efficacy of this approach.
BibTeX
@inproceedings{he2023case,
  author = {Shengxiu He and Liang Wang and Yan Sun and Huakun Du and Xiao-Min Yu},
  title = {{Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer}},
  booktitle = {Frontiers in Immunology},
  year = {2023},
  doi = {10.3389/fimmu.2023.1270828},
}
Figure